Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00817505 · ClinicalTrials.gov registry record · Phase 1
To Evaluate the Bioavailability of a Tablet of AZD1656
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
NCT00817505: Completed Phase 1 study, sponsored by AstraZeneca.
NCT00817505 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 11 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (82% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00817505, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
To evaluate the bioavailability of a tablet of AZD1656.
Interventions
- DRUG AZD1656
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2008-12 |
| Est. Completion | 2009-09 |
| Phase | Phase 1 |
What the finished NCT00817505 record still lists
NCT00817505 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 11 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (82% lower).
The record links to 0 conditions, and to 1 intervention - of which AZD1656 is the first listed.
NCT00817505 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00817505 about?
NCT00817505 is a clinical study titled "To Evaluate the Bioavailability of a Tablet of AZD1656". To evaluate the bioavailability of a tablet of AZD1656.
What is the current status of trial NCT00817505?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2008-12. Estimated completion is 2009-09.
What interventions are being tested in trial NCT00817505?
The interventions under investigation include: AZD1656 (DRUG).
Who is sponsoring clinical trial NCT00817505?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00817505's enrollment target sits among peer trials
11 1911th of 2000 higher than 88 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03114462 · 11 participants · Phase 1
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
- NCT06039709 · 11 participants · Phase 1
Sonodynamic Therapy in Patients With Recurrent GBM
- NCT06425380 · 11 participants · NA
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
- NCT06472661 · 11 participants · Early Phase 1
FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia